Tessier-Lavigne Marc 4

4 · Denali Therapeutics Inc. · Filed Jun 5, 2023

Form 4

Period: 2023-06-01

Director

Transactions

Award
Stock Option (right to buy)
2023-06-01+12,649→ 12,649 total
Exercise: $30.92Exp: 2033-06-01→ Common Stock (12,649 underlying)
Award
Common Stock
2023-06-01+4,216→ 1,874,572 total

Holdings

Footnotes (6)

[F1]Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
[F2]Includes 4,216 unvested RSUs.
[F3]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
[F4]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
[F5]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
[F6]100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Documents

1 file